Drug intelligence / Profile preview

Shenqing capsule

Development stage: Unknown
Lead developer: Longhua Hospital Shanghai University of Traditional Chinese Medicine
Modality: Small Molecules
Administration: Oral

Overview

Shenqing capsule is a Traditional Chinese Medicine (TCM) formulation currently under investigation for the treatment of mild to moderate active ulcerative colitis. It is administered orally as a capsule. The specific mechanism of action and detailed active ingredients are not publicly detailed in the provided context. It is being evaluated in a multicenter, randomized, double-blinded, parallelly positive controlled study.

Other names: 参青胶囊

Beyond the preview

Go deeper on Shenqing capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenqing capsule.

Explore the full profile